The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.
 
Zofia Piotrowska
No Relationships to Disclose
 
Daniel Botelho Costa
Honoraria - Boehringer Ingelheim; Pfizer
 
Mark Huberman
No Relationships to Disclose
 
Geoffrey R. Oxnard
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - Patent pending
 
Justin F. Gainor
Consulting or Advisory Role - Boehringer Ingelheim; Jounce Therapeutics; Kyowa Hakko Kirin
Research Funding - AstraZeneca; Bristol-Myers Squibb; Genentech; Novartis
 
Rebecca Suk Heist
Consulting or Advisory Role - Boehringer Ingelheim; Momenta Pharmaceuticals
Research Funding - Celgene; Debiopharm Group; Exelixis; Genentech/Roche; GlaxoSmithKline; Mirati Therapeutics; Peregrine Pharmaceuticals; Sanofi
 
Alona Muzikansky
No Relationships to Disclose
 
Alice Tsang Shaw
Honoraria - Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Genentech; Ignyta; Novartis; Pfizer; Roche Pharma AG
Research Funding - ARIAD; Genentech; Novartis; Pfizer
 
Matthew J. Niederst
No Relationships to Disclose
 
Linnea Fulton
No Relationships to Disclose
 
Jeffrey A. Engelman
Stock and Other Ownership Interests - Agios; GATEKEEPER Pharmaceuticals; Loxo
Consulting or Advisory Role - Agios; Aisling Capital; Amgen; AVEO; Biodesix; Cell Signaling Technology; Chugai Pharma; CytomX Therapeutics; Endo Pharmaceuticals; FSC Pediatrics; G1 Therapeutics; GATEKEEPER Pharmaceuticals; Genentech/Roche; GlaxoSmithKline; Janssen; Loxo; Merck; Novartis; Red Sky; Sanofi; Third Rock Ventures; Ventana Medical Systems
Speakers' Bureau - Chugai Pharma; Sanofi
Research Funding - Amgen; AstraZeneca; Jounce Therapeutics; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - Ventana Medical Systems
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Endo Pharmaceuticals; Genentech/Roche; Loxo; Novartis; Sanofi; Ventana Medical Systems
 
Lecia V. Sequist
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genentech; GlaxoSmithKline; Merrimack; Novartis; Taiho Pharmaceutical
Research Funding - ArQule (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)